Thomas Powles, MD, of Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, and Queen Mary University of London, discusses overall survival results from the phase III KEYNOTE-564 study of adjuvant pembrolizumab vs placebo in patients with clear cell renal cell carcinoma (Abstract LBA359).
Umang Swami, MD, of Huntsman Cancer Institute at the University of Utah, describes the molecular and immunologic mechanisms of metastatic tropism in advanced prostate cancer, data that may facilitate future drug development. In patients with metastatic disease, specific sites are associated with differential overall survival, but the biological reasons have not been fully explored (Abstract 21).
Michiel S. Van Der Heijden, MD, PhD, of the Netherlands Cancer Institute, discusses phase III results from the global EV-302 study, showing that enfortumab vedotin-ejfv plus pembrolizumab improves outcomes in patients with previously untreated locally advanced metastatic urothelial carcinoma compared with chemotherapy. Overall survival benefit was observed across select prespecified subgroups. According to Dr. Van Der Heijden, this immunotherapy combination is a potential new standard of care for first-line locally advanced metastatic urothelial carcinoma (Abstract LBA530).
Enrique Grande, MD, of MD Anderson Cancer Center Madrid, discusses findings from the CABATEN/GETNE-T1914 study, in which cabozantinib plus atezolizumab showed modest activity in patients with locally advanced or metastatic adrenocortical carcinoma, a rare malignancy with a poor prognosis and limited therapeutic options. According to Dr. Grande, the existence of long-lasting responders makes it worthwhile to continue investigating predictive factors that may help to select patients for this combination therapy (Abstract 1).
Neeraj Agarwal, MD, of Huntsman Cancer Institute at the University of Utah, discusses results of the CONTACT-2 trial, which showed cabozantinib plus atezolizumab improved radiographic progression–free survival of patients with metastatic castration-resistant prostate cancer vs a second novel hormonal therapy (NHT) in patients who had experienced disease progression on a prior NHT and have extrapelvic nodal or visceral disease. The benefits were more pronounced in patients with liver metastasis and in those who previously received docetaxel (Abstract 18).
David H. Aggen, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses reportedly the first data to describe an inverse correlation between HER2 immunohistochemistry expression and PD-L1 combined positive score. According to Dr. Aggen, these and other findings by his team may provide a foundation for further HER2-directed advanced bladder cancer studies (Abstract 538).
